In This Article:
Amidst a turbulent start to the year, global markets have been grappling with inflation concerns and political uncertainties, leading to declines in major indices and heightened volatility. As investors navigate these choppy waters, identifying stocks that are trading below their intrinsic value can present potential opportunities for those looking to capitalize on market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Türkiye Sise Ve Cam Fabrikalari (IBSE:SISE) | TRY39.32 | TRY78.59 | 50% |
| Decisive Dividend (TSXV:DE) | CA$5.96 | CA$11.89 | 49.9% |
| Elekta (OM:EKTA B) | SEK61.10 | SEK122.02 | 49.9% |
| Zhende Medical (SHSE:603301) | CN¥21.00 | CN¥41.91 | 49.9% |
| Meriaura Group Oyj (OM:MERIS) | SEK0.49 | SEK0.98 | 50% |
| Constellium (NYSE:CSTM) | US$10.32 | US$20.58 | 49.9% |
| Shinko Electric Industries (TSE:6967) | ¥5865.00 | ¥11696.51 | 49.9% |
| Andrada Mining (AIM:ATM) | £0.0235 | £0.047 | 49.8% |
| AK Medical Holdings (SEHK:1789) | HK$4.28 | HK$8.52 | 49.8% |
| Jiangsu Chuanzhiboke Education Technology (SZSE:003032) | CN¥9.20 | CN¥18.39 | 50% |
Underneath we present a selection of stocks filtered out by our screen.
China International Capital
Overview: China International Capital Corporation Limited offers financial services both in Mainland China and internationally, with a market capitalization of HK$117.51 billion.
Operations: Revenue segments for China International Capital Corporation Limited include financial services provided both domestically and internationally.
Estimated Discount To Fair Value: 25%
China International Capital is trading at HK$12.26, significantly below its estimated fair value of HK$16.34, suggesting it may be undervalued based on cash flows. Despite a forecasted earnings growth of 24.9% per year, recent results show declining revenue and net income compared to the previous year. The resignation of a non-executive director won't affect board operations, maintaining stability amidst these financial challenges.
Shanghai MicroPort EP MedTech
Overview: Shanghai MicroPort EP MedTech Co., Ltd. specializes in the research, development, production, and sale of medical devices for electrophysiological interventional diagnosis and ablation therapy, with a market cap of CN¥8.19 billion.
Operations: The company generates revenue of CN¥383.99 million from its surgical and medical equipment segment, focusing on electrophysiological interventional diagnosis and ablation therapy.